Wegovy

News

ESC: Real-world study gives Wegovy edge over Lilly rival

Novo Nordisk has latched onto a real-world study that found its weight-loss drug Wegovy works better than Eli Lilly's fast-growing rival Zepbound.

News

Novo Nordisk cuts GLP-1 prices for cash buyers

Novo Nordisk has said it will offer diabetes therapy Ozempic at $499 per month for cash-paying customers in the US.

News

Novo Nordisk claims first GLP-1 approval in MASH

Under pressure from rivals in the GLP-1 space, Novo Nordisk has been given a leg-up with a first-in-class approval for Wegovy in liver disease MASH.

News

Novo Nordisk weakens again on interim results readout

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.

News

Noom Med app and accompanying GLP-1 implements

Noom expands its GLP-1 range with 'microdose' package

Noom is offering 'microdoses' of semaglutide at a knock-down price, claiming they can prevent side effects but remain effective for weight loss.

News

Novo Nordisk slumps as it cuts sales forecast, names new CEO

Novo Nordisk has a new CEO, facing an uphill battle to restore the fortunes of its US business as diabetes and obesity drugs come under pressure.

ESC: Real-world study gives Wegovy edge over Lilly rival

Novo Nordisk cuts GLP-1 prices for cash buyers

Novo Nordisk claims first GLP-1 approval in MASH

Novo Nordisk weakens again on interim results readout

Noom expands its GLP-1 range with 'microdose' package

Novo Nordisk slumps as it cuts sales forecast, names new CEO

FDA points to liver injury with Amgen's Tavneos

Using AI-driven synthetic personas to take your insights fur...

Wegovy

Editor's Picks